nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—LIPF—testis—muscle cancer	0.0322	0.0897	CbGeAlD
Orlistat—DAGLA—tendon—muscle cancer	0.0251	0.0698	CbGeAlD
Orlistat—DAGLA—head—muscle cancer	0.0215	0.0598	CbGeAlD
Orlistat—DAGLA—testis—muscle cancer	0.0208	0.0578	CbGeAlD
Orlistat—DAGLB—tendon—muscle cancer	0.0194	0.0541	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—muscle cancer	0.0182	1	CbGdCrCtD
Orlistat—DAGLB—testis—muscle cancer	0.0161	0.0448	CbGeAlD
Orlistat—ABHD12—cardiac atrium—muscle cancer	0.0158	0.0441	CbGeAlD
Orlistat—PLA2G7—tendon—muscle cancer	0.0157	0.0437	CbGeAlD
Orlistat—PLA2G7—bone marrow—muscle cancer	0.0152	0.0423	CbGeAlD
Orlistat—ABHD16A—tendon—muscle cancer	0.0147	0.041	CbGeAlD
Orlistat—PLA2G7—vagina—muscle cancer	0.0146	0.0406	CbGeAlD
Orlistat—ABHD16A—bone marrow—muscle cancer	0.0143	0.0397	CbGeAlD
Orlistat—ABHD12—tendon—muscle cancer	0.0138	0.0384	CbGeAlD
Orlistat—ABHD16A—vagina—muscle cancer	0.0137	0.0381	CbGeAlD
Orlistat—ABHD12—vagina—muscle cancer	0.0128	0.0357	CbGeAlD
Orlistat—DAGLB—N-cadherin signaling events—CNR1—muscle cancer	0.0125	0.0879	CbGpPWpGaD
Orlistat—DAGLA—N-cadherin signaling events—CNR1—muscle cancer	0.0125	0.0879	CbGpPWpGaD
Orlistat—ABHD16A—testis—muscle cancer	0.0122	0.034	CbGeAlD
Orlistat—PNLIP—head—muscle cancer	0.0118	0.033	CbGeAlD
Orlistat—ABHD12—testis—muscle cancer	0.0114	0.0318	CbGeAlD
Orlistat—FASN—vagina—muscle cancer	0.0107	0.0299	CbGeAlD
Orlistat—FASN—testis—muscle cancer	0.00959	0.0267	CbGeAlD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.00935	0.0658	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—TIMM10—muscle cancer	0.00777	0.0547	CbGpPWpGaD
Orlistat—PLA2G4A—smooth muscle tissue—muscle cancer	0.00741	0.0206	CbGeAlD
Orlistat—FASN—p73 transcription factor network—TP73—muscle cancer	0.00718	0.0505	CbGpPWpGaD
Orlistat—PLA2G4A—renal system—muscle cancer	0.00713	0.0199	CbGeAlD
Orlistat—FASN—p73 transcription factor network—TP63—muscle cancer	0.00617	0.0435	CbGpPWpGaD
Orlistat—PLA2G4A—tendon—muscle cancer	0.00557	0.0155	CbGeAlD
Orlistat—FASN—p73 transcription factor network—WT1—muscle cancer	0.00544	0.0383	CbGpPWpGaD
Orlistat—PLA2G4A—bone marrow—muscle cancer	0.00539	0.015	CbGeAlD
Orlistat—PLA2G4A—vagina—muscle cancer	0.00517	0.0144	CbGeAlD
Orlistat—PLA2G4A—testis—muscle cancer	0.00461	0.0128	CbGeAlD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.00277	0.0195	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	0.00275	0.0194	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	0.00267	0.0188	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—ANGPT2—muscle cancer	0.00253	0.0178	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ANGPT2—muscle cancer	0.00253	0.0178	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.00239	0.0168	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.00239	0.0168	CbGpPWpGaD
Orlistat—CYP3A4—renal system—muscle cancer	0.00235	0.00655	CbGeAlD
Orlistat—PLA2G4A—AGE/RAGE pathway—FOXO4—muscle cancer	0.00197	0.0139	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—MDM2—muscle cancer	0.00176	0.0124	CbGpPWpGaD
Orlistat—Infestation NOS—Etoposide—muscle cancer	0.00176	0.00366	CcSEcCtD
Orlistat—Infestation—Etoposide—muscle cancer	0.00176	0.00366	CcSEcCtD
Orlistat—Mediastinal disorder—Vincristine—muscle cancer	0.00176	0.00365	CcSEcCtD
Orlistat—Renal failure—Etoposide—muscle cancer	0.00173	0.0036	CcSEcCtD
Orlistat—Neuropathy peripheral—Etoposide—muscle cancer	0.00172	0.00359	CcSEcCtD
Orlistat—Alopecia—Vincristine—muscle cancer	0.00172	0.00358	CcSEcCtD
Orlistat—Malaise—Dactinomycin—muscle cancer	0.00171	0.00356	CcSEcCtD
Orlistat—Mental disorder—Vincristine—muscle cancer	0.00171	0.00355	CcSEcCtD
Orlistat—Neoplasm—Methotrexate—muscle cancer	0.0017	0.00354	CcSEcCtD
Orlistat—Urine output increased—Methotrexate—muscle cancer	0.0017	0.00354	CcSEcCtD
Orlistat—Hepatobiliary disease—Etoposide—muscle cancer	0.00166	0.00346	CcSEcCtD
Orlistat—Back pain—Vincristine—muscle cancer	0.00164	0.00341	CcSEcCtD
Orlistat—Vaginal inflammation—Doxorubicin—muscle cancer	0.00163	0.00339	CcSEcCtD
Orlistat—Myalgia—Dactinomycin—muscle cancer	0.00162	0.00336	CcSEcCtD
Orlistat—Eructation—Doxorubicin—muscle cancer	0.0016	0.00333	CcSEcCtD
Orlistat—Discomfort—Dactinomycin—muscle cancer	0.0016	0.00332	CcSEcCtD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.00158	0.0111	CbGpPWpGaD
Orlistat—FASN—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.00157	0.0111	CbGpPWpGaD
Orlistat—Diabetes mellitus—Methotrexate—muscle cancer	0.00157	0.00327	CcSEcCtD
Orlistat—Urinary tract disorder—Etoposide—muscle cancer	0.00156	0.00324	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00156	0.011	CbGpPWpGaD
Orlistat—Polyuria—Methotrexate—muscle cancer	0.00156	0.00324	CcSEcCtD
Orlistat—Oedema—Dactinomycin—muscle cancer	0.00155	0.00322	CcSEcCtD
Orlistat—Urethral disorder—Etoposide—muscle cancer	0.00155	0.00322	CcSEcCtD
Orlistat—Infection—Dactinomycin—muscle cancer	0.00154	0.0032	CcSEcCtD
Orlistat—Vaginal infection—Doxorubicin—muscle cancer	0.00154	0.0032	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—KIDINS220—muscle cancer	0.00154	0.0108	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KIDINS220—muscle cancer	0.00154	0.0108	CbGpPWpGaD
Orlistat—Vertigo—Vincristine—muscle cancer	0.00152	0.00317	CcSEcCtD
Orlistat—Hepatic failure—Methotrexate—muscle cancer	0.00152	0.00317	CcSEcCtD
Orlistat—Cramps of lower extremities—Doxorubicin—muscle cancer	0.0015	0.00312	CcSEcCtD
Orlistat—Neoplasm—Doxorubicin—muscle cancer	0.00147	0.00307	CcSEcCtD
Orlistat—Convulsion—Vincristine—muscle cancer	0.00147	0.00306	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—FOXO1—muscle cancer	0.00146	0.0102	CbGpPWpGaD
Orlistat—Myalgia—Vincristine—muscle cancer	0.00144	0.00301	CcSEcCtD
Orlistat—Immune system disorder—Etoposide—muscle cancer	0.00143	0.00297	CcSEcCtD
Orlistat—Mediastinal disorder—Etoposide—muscle cancer	0.00142	0.00296	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00141	0.00294	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	0.0014	0.00985	CbGpPWpGaD
Orlistat—Alopecia—Etoposide—muscle cancer	0.0014	0.0029	CcSEcCtD
Orlistat—Anaphylactic shock—Vincristine—muscle cancer	0.00138	0.00288	CcSEcCtD
Orlistat—Oedema—Vincristine—muscle cancer	0.00138	0.00288	CcSEcCtD
Orlistat—Infection—Vincristine—muscle cancer	0.00138	0.00286	CcSEcCtD
Orlistat—Osteoarthritis—Methotrexate—muscle cancer	0.00137	0.00284	CcSEcCtD
Orlistat—Diabetes mellitus—Doxorubicin—muscle cancer	0.00136	0.00283	CcSEcCtD
Orlistat—Nervous system disorder—Vincristine—muscle cancer	0.00136	0.00283	CcSEcCtD
Orlistat—Decreased appetite—Dactinomycin—muscle cancer	0.00135	0.0028	CcSEcCtD
Orlistat—Dysgeusia—Etoposide—muscle cancer	0.00135	0.0028	CcSEcCtD
Orlistat—Hyperhidrosis—Vincristine—muscle cancer	0.00134	0.00279	CcSEcCtD
Orlistat—Fatigue—Dactinomycin—muscle cancer	0.00134	0.00278	CcSEcCtD
Orlistat—Back pain—Etoposide—muscle cancer	0.00133	0.00277	CcSEcCtD
Orlistat—Pain—Dactinomycin—muscle cancer	0.00133	0.00276	CcSEcCtD
Orlistat—Muscle spasms—Etoposide—muscle cancer	0.00132	0.00275	CcSEcCtD
Orlistat—Eczema—Doxorubicin—muscle cancer	0.00132	0.00274	CcSEcCtD
Orlistat—Hepatic failure—Doxorubicin—muscle cancer	0.00132	0.00274	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—IGF2—muscle cancer	0.00128	0.00901	CbGpPWpGaD
Orlistat—Feeling abnormal—Dactinomycin—muscle cancer	0.00128	0.00266	CcSEcCtD
Orlistat—Ill-defined disorder—Etoposide—muscle cancer	0.00128	0.00265	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—KIDINS220—muscle cancer	0.00127	0.00897	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00127	0.00264	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00126	0.00262	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—muscle cancer	0.00126	0.00262	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—muscle cancer	0.00125	0.00261	CcSEcCtD
Orlistat—Insomnia—Vincristine—muscle cancer	0.00125	0.00261	CcSEcCtD
Orlistat—Paraesthesia—Vincristine—muscle cancer	0.00124	0.00259	CcSEcCtD
Orlistat—Malaise—Etoposide—muscle cancer	0.00124	0.00258	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—muscle cancer	0.00124	0.00258	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—muscle cancer	0.00124	0.00257	CcSEcCtD
Orlistat—Vertigo—Etoposide—muscle cancer	0.00124	0.00257	CcSEcCtD
Orlistat—DAGLB—Hemostasis—IGF2—muscle cancer	0.00123	0.00868	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IGF2—muscle cancer	0.00123	0.00868	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—FH—muscle cancer	0.00123	0.00865	CbGpPWpGaD
Orlistat—Abdominal pain—Dactinomycin—muscle cancer	0.00123	0.00255	CcSEcCtD
Orlistat—Body temperature increased—Dactinomycin—muscle cancer	0.00123	0.00255	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—muscle cancer	0.00121	0.00252	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—muscle cancer	0.0012	0.0025	CcSEcCtD
Orlistat—Cough—Etoposide—muscle cancer	0.0012	0.0025	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—muscle cancer	0.0012	0.00249	CcSEcCtD
Orlistat—Fatigue—Vincristine—muscle cancer	0.00119	0.00248	CcSEcCtD
Orlistat—Convulsion—Etoposide—muscle cancer	0.00119	0.00248	CcSEcCtD
Orlistat—Pain—Vincristine—muscle cancer	0.00118	0.00246	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—muscle cancer	0.00118	0.00246	CcSEcCtD
Orlistat—Asthma—Methotrexate—muscle cancer	0.00118	0.00246	CcSEcCtD
Orlistat—Chest pain—Etoposide—muscle cancer	0.00117	0.00243	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00116	0.00242	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—muscle cancer	0.00116	0.00241	CcSEcCtD
Orlistat—Discomfort—Etoposide—muscle cancer	0.00116	0.00241	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00115	0.00811	CbGpPWpGaD
Orlistat—Hypersensitivity—Dactinomycin—muscle cancer	0.00114	0.00238	CcSEcCtD
Orlistat—Abdominal discomfort—Methotrexate—muscle cancer	0.00113	0.00236	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—muscle cancer	0.00113	0.00236	CcSEcCtD
Orlistat—FASN—AMPK Signaling—TP53—muscle cancer	0.00113	0.00793	CbGpPWpGaD
Orlistat—Anaphylactic shock—Etoposide—muscle cancer	0.00112	0.00233	CcSEcCtD
Orlistat—Infection—Etoposide—muscle cancer	0.00111	0.00232	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—muscle cancer	0.00111	0.00231	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.0011	0.00776	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Methotrexate—muscle cancer	0.0011	0.00228	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—muscle cancer	0.00109	0.00228	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—muscle cancer	0.00109	0.00228	CcSEcCtD
Orlistat—Skin disorder—Etoposide—muscle cancer	0.00109	0.00227	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—muscle cancer	0.00109	0.00226	CcSEcCtD
Orlistat—Hyperhidrosis—Etoposide—muscle cancer	0.00108	0.00226	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—muscle cancer	0.00108	0.00225	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—muscle cancer	0.00108	0.00224	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—muscle cancer	0.00107	0.00223	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—muscle cancer	0.00106	0.00221	CcSEcCtD
Orlistat—Infestation—Methotrexate—muscle cancer	0.00105	0.00219	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—muscle cancer	0.00105	0.00219	CcSEcCtD
Orlistat—PLA2G4A—Arachidonic acid metabolism—PTGS2—muscle cancer	0.00105	0.0074	CbGpPWpGaD
Orlistat—Depression—Methotrexate—muscle cancer	0.00105	0.00219	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—muscle cancer	0.00105	0.00218	CcSEcCtD
Orlistat—Renal failure—Methotrexate—muscle cancer	0.00104	0.00215	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—muscle cancer	0.00103	0.00214	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—PTCH1—muscle cancer	0.00102	0.00721	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTCH1—muscle cancer	0.00102	0.00721	CbGpPWpGaD
Orlistat—Asthma—Doxorubicin—muscle cancer	0.00102	0.00213	CcSEcCtD
Orlistat—Influenza—Doxorubicin—muscle cancer	0.00102	0.00213	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—muscle cancer	0.00102	0.00212	CcSEcCtD
Orlistat—Paraesthesia—Etoposide—muscle cancer	0.00101	0.0021	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—muscle cancer	0.001	0.00209	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.001	0.00706	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.001	0.00706	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Methotrexate—muscle cancer	0.000996	0.00207	CcSEcCtD
Orlistat—Asthenia—Vincristine—muscle cancer	0.000994	0.00207	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—muscle cancer	0.000986	0.00205	CcSEcCtD
Orlistat—Rash—Dactinomycin—muscle cancer	0.000977	0.00203	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—muscle cancer	0.000975	0.00203	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—muscle cancer	0.000969	0.00201	CcSEcCtD
Orlistat—Fatigue—Etoposide—muscle cancer	0.000967	0.00201	CcSEcCtD
Orlistat—Pain—Etoposide—muscle cancer	0.000959	0.002	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CNR1—muscle cancer	0.000953	0.00671	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CNR1—muscle cancer	0.000953	0.00671	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000951	0.00198	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—muscle cancer	0.000951	0.00198	CcSEcCtD
Orlistat—Diarrhoea—Vincristine—muscle cancer	0.000948	0.00197	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—muscle cancer	0.000946	0.00197	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—muscle cancer	0.000946	0.00197	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—muscle cancer	0.000939	0.00195	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—muscle cancer	0.000934	0.00194	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—muscle cancer	0.000927	0.00193	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—muscle cancer	0.000924	0.00192	CcSEcCtD
Orlistat—Nausea—Dactinomycin—muscle cancer	0.000921	0.00192	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—muscle cancer	0.000917	0.00191	CcSEcCtD
Orlistat—Dizziness—Vincristine—muscle cancer	0.000916	0.00191	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—muscle cancer	0.000912	0.0019	CcSEcCtD
Orlistat—Infestation—Doxorubicin—muscle cancer	0.000912	0.0019	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—muscle cancer	0.000897	0.00187	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000894	0.00186	CcSEcCtD
Orlistat—Urticaria—Etoposide—muscle cancer	0.000891	0.00185	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—muscle cancer	0.000887	0.00184	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—muscle cancer	0.000887	0.00184	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—muscle cancer	0.000887	0.00184	CcSEcCtD
Orlistat—Vomiting—Vincristine—muscle cancer	0.000881	0.00183	CcSEcCtD
Orlistat—Rash—Vincristine—muscle cancer	0.000873	0.00182	CcSEcCtD
Orlistat—Dermatitis—Vincristine—muscle cancer	0.000872	0.00181	CcSEcCtD
Orlistat—FASN—Metabolism—FH—muscle cancer	0.000869	0.00612	CbGpPWpGaD
Orlistat—Headache—Vincristine—muscle cancer	0.000868	0.0018	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CNR1—muscle cancer	0.000865	0.00609	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CNR1—muscle cancer	0.000865	0.00609	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000863	0.0018	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—muscle cancer	0.000856	0.00178	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—muscle cancer	0.000854	0.00178	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—muscle cancer	0.000852	0.00177	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000842	0.00593	CbGpPWpGaD
Orlistat—Alopecia—Methotrexate—muscle cancer	0.000836	0.00174	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000833	0.00586	CbGpPWpGaD
Orlistat—Mental disorder—Methotrexate—muscle cancer	0.000829	0.00172	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—muscle cancer	0.000827	0.00172	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—muscle cancer	0.000823	0.00171	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—muscle cancer	0.000823	0.00171	CcSEcCtD
Orlistat—Nausea—Vincristine—muscle cancer	0.000823	0.00171	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—muscle cancer	0.000819	0.0017	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—muscle cancer	0.000819	0.0017	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—muscle cancer	0.000813	0.00169	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—muscle cancer	0.000809	0.00168	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—muscle cancer	0.000807	0.00168	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—muscle cancer	0.000806	0.00168	CcSEcCtD
Orlistat—Asthenia—Etoposide—muscle cancer	0.000805	0.00167	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—muscle cancer	0.000803	0.00167	CcSEcCtD
Orlistat—Back pain—Methotrexate—muscle cancer	0.000796	0.00166	CcSEcCtD
Orlistat—Pruritus—Etoposide—muscle cancer	0.000794	0.00165	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—muscle cancer	0.000776	0.00161	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—muscle cancer	0.000768	0.0016	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—muscle cancer	0.000764	0.00159	CcSEcCtD
Orlistat—PNLIP—Disease—ENO2—muscle cancer	0.000756	0.00532	CbGpPWpGaD
Orlistat—Malaise—Methotrexate—muscle cancer	0.000743	0.00154	CcSEcCtD
Orlistat—Dizziness—Etoposide—muscle cancer	0.000742	0.00154	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—muscle cancer	0.00074	0.00154	CcSEcCtD
Orlistat—Vertigo—Methotrexate—muscle cancer	0.00074	0.00154	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—muscle cancer	0.000738	0.00154	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—muscle cancer	0.000724	0.00151	CcSEcCtD
Orlistat—Cough—Methotrexate—muscle cancer	0.000718	0.00149	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—muscle cancer	0.000718	0.00149	CcSEcCtD
Orlistat—Convulsion—Methotrexate—muscle cancer	0.000713	0.00148	CcSEcCtD
Orlistat—Vomiting—Etoposide—muscle cancer	0.000713	0.00148	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—muscle cancer	0.000713	0.00148	CcSEcCtD
Orlistat—Rash—Etoposide—muscle cancer	0.000707	0.00147	CcSEcCtD
Orlistat—Dermatitis—Etoposide—muscle cancer	0.000707	0.00147	CcSEcCtD
Orlistat—Headache—Etoposide—muscle cancer	0.000703	0.00146	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—muscle cancer	0.000703	0.00146	CcSEcCtD
Orlistat—Chest pain—Methotrexate—muscle cancer	0.000701	0.00146	CcSEcCtD
Orlistat—Myalgia—Methotrexate—muscle cancer	0.000701	0.00146	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—muscle cancer	0.000698	0.00145	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000696	0.00145	CcSEcCtD
Orlistat—PNLIP—Metabolism—MED12—muscle cancer	0.000694	0.00489	CbGpPWpGaD
Orlistat—Discomfort—Methotrexate—muscle cancer	0.000693	0.00144	CcSEcCtD
Orlistat—Back pain—Doxorubicin—muscle cancer	0.00069	0.00143	CcSEcCtD
Orlistat—PNLIP—Disease—HMGA1—muscle cancer	0.000687	0.00483	CbGpPWpGaD
Orlistat—Muscle spasms—Doxorubicin—muscle cancer	0.000685	0.00143	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—muscle cancer	0.000672	0.0014	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—muscle cancer	0.000672	0.0014	CcSEcCtD
Orlistat—Infection—Methotrexate—muscle cancer	0.000668	0.00139	CcSEcCtD
Orlistat—Nausea—Etoposide—muscle cancer	0.000666	0.00139	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—muscle cancer	0.000662	0.00138	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—muscle cancer	0.000659	0.00137	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—muscle cancer	0.000653	0.00136	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—muscle cancer	0.00065	0.00135	CcSEcCtD
Orlistat—Malaise—Doxorubicin—muscle cancer	0.000643	0.00134	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—muscle cancer	0.000641	0.00133	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—ANGPT2—muscle cancer	0.000638	0.00449	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ENO2—muscle cancer	0.000633	0.00446	CbGpPWpGaD
Orlistat—Palpitations—Doxorubicin—muscle cancer	0.00063	0.00131	CcSEcCtD
Orlistat—Cough—Doxorubicin—muscle cancer	0.000622	0.00129	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—muscle cancer	0.000618	0.00129	CcSEcCtD
Orlistat—PNLIP—Disease—FOXO4—muscle cancer	0.000616	0.00434	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000612	0.00127	CcSEcCtD
Orlistat—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000608	0.00428	CbGpPWpGaD
Orlistat—Insomnia—Methotrexate—muscle cancer	0.000608	0.00126	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—muscle cancer	0.000607	0.00126	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—muscle cancer	0.000607	0.00126	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PTCH1—muscle cancer	0.000605	0.00426	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTCH1—muscle cancer	0.000605	0.00426	CbGpPWpGaD
Orlistat—Anxiety—Doxorubicin—muscle cancer	0.000605	0.00126	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—muscle cancer	0.000603	0.00126	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000603	0.00125	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000602	0.00423	CbGpPWpGaD
Orlistat—Discomfort—Doxorubicin—muscle cancer	0.0006	0.00125	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—muscle cancer	0.000594	0.00123	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—muscle cancer	0.000592	0.00123	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—muscle cancer	0.000584	0.00122	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—muscle cancer	0.000582	0.00121	CcSEcCtD
Orlistat—Oedema—Doxorubicin—muscle cancer	0.000582	0.00121	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00058	0.00121	CcSEcCtD
Orlistat—Fatigue—Methotrexate—muscle cancer	0.000579	0.00121	CcSEcCtD
Orlistat—Infection—Doxorubicin—muscle cancer	0.000578	0.0012	CcSEcCtD
Orlistat—Pain—Methotrexate—muscle cancer	0.000575	0.0012	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—muscle cancer	0.000571	0.00119	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—muscle cancer	0.000565	0.00118	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—muscle cancer	0.000563	0.00117	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—muscle cancer	0.000554	0.00115	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—muscle cancer	0.000549	0.00114	CcSEcCtD
Orlistat—FASN—Disease—ENO2—muscle cancer	0.000535	0.00376	CbGpPWpGaD
Orlistat—Urticaria—Methotrexate—muscle cancer	0.000534	0.00111	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—muscle cancer	0.000531	0.00111	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—muscle cancer	0.000531	0.00111	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00053	0.0011	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—muscle cancer	0.000526	0.00109	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—muscle cancer	0.000522	0.00109	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—FOXO4—muscle cancer	0.000521	0.00366	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FOXO4—muscle cancer	0.000521	0.00366	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—VEGFA—muscle cancer	0.000517	0.00364	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—VEGFA—muscle cancer	0.000517	0.00364	CbGpPWpGaD
Orlistat—Dyspepsia—Doxorubicin—muscle cancer	0.000512	0.00107	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CNR1—muscle cancer	0.000511	0.0036	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CNR1—muscle cancer	0.000511	0.0036	CbGpPWpGaD
Orlistat—Decreased appetite—Doxorubicin—muscle cancer	0.000506	0.00105	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000502	0.00105	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTCH1—muscle cancer	0.000502	0.00353	CbGpPWpGaD
Orlistat—Fatigue—Doxorubicin—muscle cancer	0.000502	0.00104	CcSEcCtD
Orlistat—Pain—Doxorubicin—muscle cancer	0.000498	0.00104	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—muscle cancer	0.000495	0.00103	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000495	0.00348	CbGpPWpGaD
Orlistat—FASN—Metabolism—MED12—muscle cancer	0.000491	0.00346	CbGpPWpGaD
Orlistat—FASN—Disease—HMGA1—muscle cancer	0.000486	0.00342	CbGpPWpGaD
Orlistat—Asthenia—Methotrexate—muscle cancer	0.000482	0.001	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—muscle cancer	0.000479	0.000998	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000476	0.00099	CcSEcCtD
Orlistat—Pruritus—Methotrexate—muscle cancer	0.000475	0.000989	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000473	0.00333	CbGpPWpGaD
Orlistat—Urticaria—Doxorubicin—muscle cancer	0.000462	0.000962	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—muscle cancer	0.00046	0.000957	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—muscle cancer	0.00046	0.000957	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—muscle cancer	0.00046	0.000956	CcSEcCtD
Orlistat—PNLIP—Disease—FOXO1—muscle cancer	0.000455	0.0032	CbGpPWpGaD
Orlistat—FASN—Metabolism—ENO2—muscle cancer	0.000448	0.00315	CbGpPWpGaD
Orlistat—Dizziness—Methotrexate—muscle cancer	0.000444	0.000924	CcSEcCtD
Orlistat—FASN—Disease—FOXO4—muscle cancer	0.000436	0.00307	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FOXO4—muscle cancer	0.000431	0.00304	CbGpPWpGaD
Orlistat—Hypersensitivity—Doxorubicin—muscle cancer	0.000429	0.000892	CcSEcCtD
Orlistat—Vomiting—Methotrexate—muscle cancer	0.000427	0.000889	CcSEcCtD
Orlistat—Rash—Methotrexate—muscle cancer	0.000424	0.000881	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CNR1—muscle cancer	0.000423	0.00298	CbGpPWpGaD
Orlistat—Dermatitis—Methotrexate—muscle cancer	0.000423	0.000881	CcSEcCtD
Orlistat—Headache—Methotrexate—muscle cancer	0.000421	0.000876	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—IGF2—muscle cancer	0.000418	0.00294	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF2—muscle cancer	0.000418	0.00294	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—muscle cancer	0.000417	0.000869	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—muscle cancer	0.000412	0.000856	CcSEcCtD
Orlistat—Nausea—Methotrexate—muscle cancer	0.000399	0.00083	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—muscle cancer	0.000398	0.000828	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TP53—muscle cancer	0.000391	0.00275	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—muscle cancer	0.000391	0.00275	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIDINS220—muscle cancer	0.000387	0.00272	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—muscle cancer	0.000385	0.0008	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—FOXO1—muscle cancer	0.000385	0.00271	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FOXO1—muscle cancer	0.000385	0.00271	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000373	0.00263	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—FH—muscle cancer	0.000373	0.00263	CbGpPWpGaD
Orlistat—Vomiting—Doxorubicin—muscle cancer	0.00037	0.00077	CcSEcCtD
Orlistat—Rash—Doxorubicin—muscle cancer	0.000367	0.000763	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—muscle cancer	0.000367	0.000763	CcSEcCtD
Orlistat—Headache—Doxorubicin—muscle cancer	0.000365	0.000758	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00036	0.00253	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.00035	0.00247	CbGpPWpGaD
Orlistat—PNLIP—Disease—KIT—muscle cancer	0.000347	0.00244	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF2—muscle cancer	0.000346	0.00244	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—muscle cancer	0.000346	0.000719	CcSEcCtD
Orlistat—FASN—Disease—FOXO1—muscle cancer	0.000322	0.00227	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FOXO1—muscle cancer	0.000319	0.00224	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF2—muscle cancer	0.00031	0.00218	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KIT—muscle cancer	0.000293	0.00206	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KIT—muscle cancer	0.000293	0.00206	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000283	0.002	CbGpPWpGaD
Orlistat—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000273	0.00192	CbGpPWpGaD
Orlistat—PNLIP—Disease—MDM2—muscle cancer	0.000273	0.00192	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—muscle cancer	0.000263	0.00185	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTCH1—muscle cancer	0.000258	0.00182	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000252	0.00178	CbGpPWpGaD
Orlistat—FASN—Disease—KIT—muscle cancer	0.000245	0.00173	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KIT—muscle cancer	0.000243	0.00171	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MDM2—muscle cancer	0.000231	0.00162	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MDM2—muscle cancer	0.000231	0.00162	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—muscle cancer	0.00022	0.00155	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CNR1—muscle cancer	0.000218	0.00153	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000214	0.00151	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MED12—muscle cancer	0.000211	0.00148	CbGpPWpGaD
Orlistat—FASN—Disease—MDM2—muscle cancer	0.000193	0.00136	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO2—muscle cancer	0.000192	0.00135	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MDM2—muscle cancer	0.000191	0.00135	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—muscle cancer	0.000186	0.00131	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—muscle cancer	0.000175	0.00123	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—muscle cancer	0.000175	0.00123	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—muscle cancer	0.000156	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTCH1—muscle cancer	0.000152	0.00107	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.00015	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—muscle cancer	0.000145	0.00102	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—muscle cancer	0.000132	0.000932	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—muscle cancer	0.000132	0.000932	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FOXO4—muscle cancer	0.000131	0.000922	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—muscle cancer	0.00013	0.000915	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CNR1—muscle cancer	0.000129	0.000905	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—muscle cancer	0.00011	0.000772	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF2—muscle cancer	0.000105	0.00074	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—muscle cancer	9.82e-05	0.000692	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FOXO1—muscle cancer	9.67e-05	0.000681	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—FH—muscle cancer	8.74e-05	0.000615	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KIT—muscle cancer	7.37e-05	0.000519	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—muscle cancer	6.69e-05	0.000471	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—muscle cancer	5.81e-05	0.000409	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MED12—muscle cancer	4.94e-05	0.000347	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—muscle cancer	4.5e-05	0.000317	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—muscle cancer	4.41e-05	0.00031	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—muscle cancer	3.33e-05	0.000234	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—muscle cancer	1.57e-05	0.00011	CbGpPWpGaD
